Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: Looking for a relationship between tolerance and outcome

Annals of Clinical Microbiology and Antimicrobials

Volumn 10, Issue , 2011, Pages

  Pasticci, Maria B ^a   Moretti, Amedeo ^a   Stagni, Giuliano ^a   Ravasio, Veronica ^b   Soavi, Laura ^b   Raglio, Annibale ^b   Vailati, Francesca ^b   Cardaccia, Angela ^a   Santucci, Antonella ^a   Papili, Rita ^a   Sgrelli, Alessio ^a   Pallotto, Carlo ^a   Baldelli, Franco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OXACILLIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; DRUG TOLERANCE; EMBOLISM; EPSILOMETER TEST; FEMALE; HEART SURGERY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NATIVE VALVE ENDOCARDITIS; PROSTHETIC VALVE ENDOCARDITIS; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; ADULT; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; OXACILLIN; RETROSPECTIVE STUDIES; SERUM BACTERICIDAL TEST; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 79958040427     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-10-26     Document Type: Article

References (26)

1. Fowler VG, Miro JM, Hoen BH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliot TS, Levine DP, Bayer AS, . ICE Investigators Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 24:3012-3021. ICE Investigators.
2. Hill EE, Herijgers P, Herregods M-C, Peetermans WE. Evolving trends in infective endocarditis. Clinic Microbiol Infect 2006, 12(1):5-12.
3. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infections. JAMA 2003, 290(22):2976-2984. 10.1001/jama.290.22.2976, 14665659.
4. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulis GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42(6):2398-2402. 10.1128/JCM.42.6.2398-2402.2004, 427878, 15184410.
5. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990, 34(12):2348-2353. 172059, 1965105.
6. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990, 34(6):1227-1231. 171789, 2393284.
7. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin susceptible clinical methicillin-resistant S.aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother 2007, 60:788-794. 10.1093/jac/dkm258, 17623693.
8. Monaco M, Sanchini A, Grudmann H. Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. Eur J Clin Microbiol Infect Dis 2010, 29:771-777. 10.1007/s10096-010-0922-2, 20401508.
9. Charles PGP, Ward PB, Johnson DR, Benjamin PH, Grayson L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004, 38:448-451. 10.1086/381093, 14727222.
10. Sakoulas G, Moellering RC, Eliooulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infec Dis 2006, 42(suppl):40-50.
11. Traczewski MM, Bradley DK, Steenbergen JN, Brown SD. Inhibitory and bactericidal activity of daptomycin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemoter 2009, 53(9):1735-1738.
12. Denny AE, Peterson R, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med 1979, 139:1026-1031. 10.1001/archinte.139.9.1026, 475520.
13. Rajashekaraiah KR, Rice T, Rao VS, Marsh D, Ramakrisna B, Kallick CA. Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis. Ann Intern Med 1980, 93(6):796-801.
14. Goldman PL, Petersdorf RG. Significance of methicillin tolerance in experimental staphylococcal endocarditis. Antimicrob Agents Chemoter 1979, 15(6):802-806.
15. French GL. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J Antimicrob Chemother 2006, 58:1107-1117. 10.1093/jac/dkl393, 17040922.
16. Clinical and Laboratory Standard Institute Performance Standards for Antimicrobial Susceptibility Testing; 18th Informational Supplement. M100-S18. 2008, Clinical and Laboratory Standard Institute, Wayne, PA, Clinical and Laboratory Standard Institute.
17. Clinical and Laboratory Standard Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 2009, Clinical and Laboratory Standard Institute, Wayne, PA, 8, M07-A8, Clinical and Laboratory Standard Institute.
18. Clinical and Laboratory Standard Institute Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. M26-A. 1999. Clinical and Laboratory Standard Institute, Wayne, PA, Clinical and Laboratory Standard Institute.
19. Miller JM. Calculating MIC50. J Antimicrob Chemother 1991, 27(6):863-864. 10.1093/jac/27.6.863, 1938695.
20. May J, Shannon K, King A, French G. Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother 1988, 42:189-197.
21. Sabath LD, Lavadiere M, Wheeler N, Blazevic D, Wilkinson BJ. A new type of penicillin resistance in Staphylococcus aureus. Lancet i 1997, 443-447.
22. Handwerger S, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis 1985, 7:368-386. 10.1093/clinids/7.3.368, 3895353.
23. Perry JD, Jones AL, Gould F. Glycopeptide tolerance in bacteria causing endocarditis. J Antimicrob Chemother 1999, 44:121-124. 10.1093/jac/44.1.121, 10459820.
24. Chen L, Mediavilla JR, Oliveira DC, Willey BM, de Lencastre H, Kreiswirth BN. Multiplex Real-Time PCR for rapid staphylococcal cassette chromosome mec typing. J Clin Microbiol 2009, 47(11):3692-3706. 10.1128/JCM.00766-09, 2772623, 19726600.
25. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(suppl):13-24.
26. Sader HS, Rhomberg PR, Jones RN. Nine-Hospital study comparing broth microdilution and E-test method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53(7):3162-3165. 10.1128/AAC.00093-09, 2704704, 19398641.